Teva
Teva launches generic Aricept in the UK
February 16, 2012Manufacturing and Production, Sales and Marketing Alzheimer's, Aricept, NHS, Pfizer, Teva
Teva has launched its generic version of Alzheimer’s drug Aricept, as the drug loses its patent protection in the UK. …
Pfizer recalls oral contraceptive for packaging errors
February 2, 2012Manufacturing and Production Akrimax, Bedford, Cephalon, Lo/Ovral-28, Pfizer, Teva
Pfizer has been forced to recall a large volume of oral contraceptive packs distributed in the US market because a …
Yanai steps down as Teva’s chief executive after four years at the helm
January 3, 2012Medical Communications Teva
Shlomo Yanai is to step down as the chief executive and president of Teva, the world’s biggest generic drug makers. …
Teva gains tentative approval to sell generic Lipitor in 2012
December 5, 2011Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
Teva has gained a tentative approval by the FDA to sell its generic form of Pfizer’s blockbuster statin Lipitor next …
FDA approves Ranbaxy’s generic Lipitor
December 1, 2011Manufacturing and Production, Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
The FDA will allow Ranbaxy to develop a generic version of Pfizer’s blockbuster statin Lipitor. The firm has received final …
Dipankar Bhattacharjee becomes vice president of Teva Northern Europe
November 21, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva
Dipankar Bhattacharjee has been promoted to vice president of UK and Teva Northern Europe. Teva said that as part of …
Ranbaxy to collaborate with Teva on generic Lipitor in US?
November 7, 2011Manufacturing and Production, Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
Israeli drugmaker Teva Pharmaceutical could get an unexpected boost from an earlier-than-expected launch of its generic version of Pfizer’s cholesterol …
Teva sees modest growth as US sales fall
November 3, 2011Business Services, Sales and Marketing Teva, generics
Sales growth at Teva was modest in Q3, rising 2% to $4.34 billion, with growth predominately coming from branded drugs.This …
Teva makes commitment to Russian manufacturing facility
September 20, 2011Manufacturing and Production, Sales and Marketing Russia, Teva
Teva has joined a number of its peers in the pharmaceutical sector and announced plans to build a new manufacturing …
Teva in the dock again for hepatitis link to propofol
August 30, 2011Manufacturing and Production Teva, manufacturing and production news, propofol
Teva’s decision to shut down a manufacturing facility for the anaesthetic propofol has become a focal point in a US …
Teva’s MS treatment disappoints
August 2, 2011Research and Development, Sales and Marketing Laquinimod, MS, Teva
Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …
Teva closes one Canadian plant, expands two more
July 22, 2011Manufacturing and Production Canada, Teva
Teva Pharmaceutical has decided to shut down its recently-acquired manufacturing Canadian facility in Montreal, Quebec, having failed to find a …
Teva’s Cephalon acquisition could be delayed
June 15, 2011Manufacturing and Production, Research and Development, Sales and Marketing Cephalon, Teva
The Federal Trade Commission has requested more information about Teva’s deal with Cephalon, potentially delaying the purchase by a month. …
Teva plans Japan expansion with Taiyo buy
May 17, 2011Sales and Marketing Taiyo, Teva, generics
Teva is to acquire a majority stake in Taiyo, Japan’s third largest generics company for $460 million in cash. The …
Generic and API firms get latest crop of FDA warning letters
May 10, 2011Manufacturing and Production Cephazone, FDA, FDA warning letter, Ningbo Smart, Teva
Generic drugmakers Teva and Cephazone and API producer Ningbo Smart are the latest companies to receive warning letters from the …
